T-Cell Receptor Clonotypes and Aggressive Subtypes in Cutaneous T-Cell Lymphoma
JAMA Dermatology · 2026
DOI: 10.1001/jamadermatol.2025.4081 ↗Kurz gefasst
Fachartikel in der Zeitschrift JAMA Dermatology, 2026. Verfasst von Liliana L Crisan und 6 weiteren Autor:innen. Beteiligte Einrichtung: Division of Dermatology, City of Hope Comprehensive Cancer Center and Beckman Research Institute, Duarte, California. Hauptthemen laut MEDLINE: Lymphoma, T-Cell, Cutaneous, Mycosis Fungoides, Receptors, Antigen, T-Cell, Receptors, Antigen, T-Cell, alpha-beta. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 34 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS.
Abstract (Originalsprache)
Importance T-cell receptor (TCR) clonotype patterns across disease stages and histologic subtypes in mycosis fungoides (MF) and Sézary syndrome (SS) remain poorly characterized, limiting their use in risk stratification.
Objectives
To assess the association of TCR β (TCRB) and γ (TCRG) clonotypes with disease stage, folliculotropism, large-cell transformation, and overall survival (OS) as well as clonal abundance (percentage of total reads) with immune checkpoint expression. Design, Setting, and Participants This retrospective cohort study conducted at City of Hope (Duarte, California) included patients with stage IA to IVB MF/SS who underwent TCR next-generation sequencing on lesional skin biopsy specimens collected between June 2020 to October 2024; duplicate samples were excluded. Analyses were performed from November 2024 to April 2025. Main Outcomes and Measures Associations between clinical and genetic categorical variables were evaluated using the Fisher exact test. OS was analyzed using Kaplan-Meier estimates, with univariate and multivariable models applied to assess prognostic factors.
Results
Of the 125 patients (42 female [33.6%] and 74 male individuals [66.4%]; mean [SD] age, 62.4 [15.9] years) who underwent TCR sequencing, at least 1 clonal TCRB and/or TCRG gene segment was identified in 98 patients (78%). Clonal TCRB and TCRG segments were detected in 72 (57.6%) and 92 patients (73.6%), respectively. The clonal Vb20 segment was significantly associated with folliculotropism and concurrent large-cell transformation compared with classic MF/SS (7 of 17 [41%] vs 0 of 30 [0%]; P < .001), marginally significantly associated with advanced-stage MF/SS compared with early-stage MF (8 of 38 [21%] vs 0 of 34 [0%]; P = .01). Clonal Vg8 was significantly associated with advanced-stage MF/SS compared with early-stage MF (25 of 53 [47%] vs 8 of 39 [21%]; P = .01) and correlated with poorer OS. Additionally, the higher percentage of total reads for TCRG was positively correlated with increased expression of immune checkpoints programmed cell death 1 and inducible T-cell costimulator but not with programmed cell death ligand 1. Conclusions and Relevance This cohort study’s analysis of TCRB and TCRG repertoires identified specific clonotypes that were associated with more aggressive subtypes and poorer survival in patients with MF/SS. Incorporating TCR sequencing into clinical practice may enhance risk stratification, enabling earlier identification of high-risk patients who could benefit from closer monitoring and timely implementation of more intensive treatment strategies in the disease course to improve clinical outcomes.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Division of Dermatology, City of Hope Comprehensive Cancer Center and Beckman Research Institute, Duarte, California.
- Division of Biostatistics, Department of Computational and Quantitative Medicine, City of Hope Comprehensive Cancer Center and Beckman Research Institute, Duarte, California.
- Department of Pathology, City of Hope Comprehensive Cancer Center and Beckman Research Institute, Duarte, California.
- Department of Hematology and Hematopoietic Cell Transplantation, City of Hope Comprehensive Cancer Center and Beckman Research Institute, Duarte, California.
- Division of Hematology/Oncology, Memorial Sloan Kettering Cancer Center, New York, New York.
Förderung
- NCI NIH HHS
Zitieren
APA
Crisan, L. L., Li, S. J., Afkhami, M., Zain, J., Rosen, S. T., Pillai, R., & Querfeld, C. (2026). T-Cell Receptor Clonotypes and Aggressive Subtypes in Cutaneous T-Cell Lymphoma. JAMA Dermatology. https://doi.org/10.1001/jamadermatol.2025.4081
Vancouver
Crisan LL, Li SJ, Afkhami M, Zain J, Rosen ST, Pillai R, et al. T-Cell Receptor Clonotypes and Aggressive Subtypes in Cutaneous T-Cell Lymphoma. JAMA Dermatology. 2026. doi:10.1001/jamadermatol.2025.4081
BibTeX
@article{Crisan2026,
author = {Crisan, Liliana L and Li, Shanpeng J and Afkhami, Michelle and Zain, Jasmine and Rosen, Steven T and Pillai, Raju and Querfeld, Christiane},
title = {T-Cell Receptor Clonotypes and Aggressive Subtypes in Cutaneous T-Cell Lymphoma},
journal = {JAMA Dermatology},
year = {2026},
doi = {10.1001/jamadermatol.2025.4081}
}
EUVIMED